Our inaugural Los Angeles Walk & Roll to Cure FSHD made the local TV news in Torrance, CA, this week! The event was organized by the Los Angeles chapter of […]
Los Angeles Walk & Roll to Cure FSHD makes the news
New biotech is developing Genea Biocells’ FSHD drug
[…] product pipeline is championed by the small molecule GBC0905 (Rebastinib) aimed at the treatment of FSHD Type 1 and Type 2. Myocea was spun out of San Diego-based Genea Biocells […]
Hot off the press – FSHD Advocate
Our new issue of the FSHD Advocate, the first of 2021, is now available online. For those of you who receive our flagship magazine by the postal service, it will […]
Extraordinary Measures – Updating the standard of care for FSHD
[…] task to update the medical profession, considering that most physicians see only a handful of FSHD patients in their career. The information from that muscular dystrophy lecture in medical school […]
Arrowhead files for regulatory clearance to start a Phase 1/2 study in FSHD
[…] (RNAi) therapeutic being developed as a potential treatment for patients with facioscapulohumeral muscular dystrophy ( FSHD). ARO-DUX4 is the first clinical candidate utilizing Arrowhead’s proprietary Targeted RNAi Molecule (TRiMTM) platform […]